Migraine Drugs Market by Type (Abortive Medicine, Preventive Medicine), Administration Route (Oral, Injection, Others), Distribution Channel (Hospital-based Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

Market Definition:

The global Migraine Drugs Market size was valued at USD 1.80 billion in 2019 and is predicted to reach USD 2.44 billion by 2030, with a CAGR of 2.8% from 2020-2030.

Migraine is a medical condition pertaining with primary headache disorder with symptoms such as nausea, vomiting, dry mouth, somnolence, and sensitivity to light or sound. The headaches start from one side of the head and are pulsating in nature. In some cases, patients are affected by prevalence of aura.

The recurrent headaches can last up to some hours or days, with intensity varying from moderate to severe. Migraine has no permanent cure, but migraine drugs can be used to reduce and prevent migraines.

Women are more prone to migraine attacks due to conditions like; menstrual migraines, menopause migraines, and migraines due to stress, hypertension, or other hormonal issues. The increasing prevalence of migraine, specifically in women as compared to men, raises the demand for effective migraine drugs, thereby propagating the growth of global migraine drugs market.

Market Dynamics and Trends:

According to the data provided by Migraine Trust in 2017, 1 in 7 people worldwide suffer from migraine, i.e. 2% of the total world population suffer from migraine; thereby, migraine being the third most common disease at global level. This scenario generates a demand for effective migraine drugs with minimal or no side-effects; hence supplementing the growth of migraine drugs market.

However, side effects associated with the intake of migraine drugs are expected to restrict the growth of migraine drugs market.

Moreover, the factors such as growing consumer awareness regarding better treatment options, increasing number of approvals granted by the U.S Food and Drug Administration, and upsurge in investments for R&D activities, are anticipated in creating several profitable opportunities for the growth of global migraine drugs market, in coming future.

Market Segmentations and Scope of the Study:

The global migraine drugs market share has been analyzed based on type, route of administration, distribution channel and geography. Based on type, the migraine drugs market is segmented into preventive medicine and abortive medicine. The abortive medicine segment is sub-segmented into Triptans (Serotonin Receptor Agonists), Ergotamine Derivative, and others. The preventive medicine is further divided into Anticonvulsant, Antidepressant, Beta Blocker, and others. Based on administration route, the market is segmented into oral, injection, others. Based on distribution channel, the migraine drugs market is divided into hospital-based pharmacies, retail pharmacies, and online pharmacies. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis:

North America denotes higher adoption of the migraine drugs and is anticipated to hold the highest market share in the global migraine drugs market throughout the forecast period. This is attributable to the factors including presence of well-established healthcare amenities, increased awareness among people, and advancements in medical technologies.

Asia Pacific is estimated to show rapid growth with developing market size, owing to increasing accessibility to healthcare facilities, and increased investment by the market players especially in the emerging economies.

Competitive Landscape:

The migraine drugs market is highly competitive and consists of various market players. Some of the major market players include Allergan Plc., Abbott Laboratories, AstraZeneca, Endo International Plc., Eisai Co. Ltd., Impax Laboratories, GlaxoSmithKline Plc., Johnson & Johnson, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Limited, Sanofi SA, and Novartis International AG, among others.

An upsurge in R&D activities and increasing approvals granted by the U.S Food and Drug Administration (FDA), for new products launched by the key players, is leading the healthcare industry to new heights, thereby creating lucrative opportunities in the global migraine drugs market.

For instance, in January 2020, Ubrogepant commercialized as Ubrelvy in the migraine drugs market was granted the FDA approval, for treating patients suffering from acute migraine with or without the prevalence of aura in adults. Ubrogepant as compared to its antagonist placebo gives fast relief from migraine symptoms such as nausea, vomiting, dry mouth, somnolence, and sensitivity to light or sound; within 2 hours of intake.

In February 2020, Biohaven announced that its NURTEC ODT-Rimegepant drug got approved by the U.S FDA, for treatment of acute migraine in adults. The studies claimed that a single oral dose of 75 mg NURTEC ODT, can provide relief to patients suffering from acute migraine condition within an hour, and its effect lasts for about 48 hours. The first-ever Calcitonin Gene-Related Peptide (CGRP) receptors, are orally dispersible tablets, that can be taken with or without water. These are known to provide fast relief even in acute migraine conditions.

In February 2020, Lundbeck, a well-known player in the migraine drugs market announced that its drug VYEPTI- eptinezumab-jjmr, got approved by the U.S FDA, for prevention and treatment of migraine in adults. VYEPTI is the first-ever intravenous (IV) treatment for migraine prevention. The clinical studies represented migraine reduction by 75% in 6 months, with a recommended dosage of 100 mg every 3 months.

KEY BENEFITS:

• The migraine drugs market report provides the quantitative analysis of the current market and estimations through 2020-2030 that assists in identifying the prevailing market opportunities to capitalize on.

• The study comprises a deep dive analysis of the migraine drugs market trend including the current and future trends for depicting the prevalent investment pockets in the market.

• The report provides detailed information related to key drivers, restraints, opportunities, and their impact on the migraine drugs market is provided in the report.

• The report incorporates competitive analysis of the market players along with their market share in the global migraine drugs market.

• The SWOT analysis and Porters Five Forces model is elaborated in the study of migraine drugs market.

• Value chain analysis in the migraine drugs market study provides a clear picture of the stakeholders’ roles.

KEY MARKET SEGMENTS:

By Type

• Abortive Medicine

  • Triptans (Serotonin Receptor Agonists)

  • Ergotamine Derivative

  • Others

• Preventive Medicine

  • Anticonvulsant

  • Antidepressant

  • Beta Blocker

  • Others

By Route of Administration

• Oral

• Injection

• Others

By Distribution Channel

• Hospital-Based Pharmacies

• Retail Pharmacies

• Online Pharmacies

By Geography

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Rest of Europe

• Asia-Pacific

  • China

  • India

  • Japan

  • Australia

  • South Korea

  • Rest of Asia-Pacific

• RoW

  • Saudi Arabia

  • South Africa

  • Brazil

  • Remaining countries

REPORT SCOPE AND SEGMENTATION:

Test